BioWorld

April 4, 2016

View Archived Issues

Complementary approaches yield new target insights

By combining two types of genomic technologies to probe the targets of an experimental antiviral drug, researchers have identified a strategy that may be able to mitigate its toxicity. Read More

Week in review

Read More

Week in Washington

Read More

Word on the street

Read More

Biotech money raised by month in 2016

Read More

Public financing of biotechnology companies: Commenced trading in March 2016

Read More

Public financing of biotechnology companies: Filed and pending IPOs

Read More

2016 top private financings of public companies

Read More

Other financings of public biotechnology companies: March 2016

Read More

2016 top financings of private companies

Read More

Venture capital & other investments in private biotechnology companies: March 2016

Read More

Milestone payments from corporate partners: March 2016

Read More

Money raised by biotech in 2016 vs. 2015

Read More

Money raised by biotech: Jan. 1 - Mar. 31, 2016

Read More

The week's biggest gainers and losers

Read More

BioWorld stock report for public biotechnology companies

Read More

BioWorld Stock Index 2016

Read More

Nasdaq Stock Index 2016

Read More